Cargando…

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and few effective treatment options. Nonetheless, recent positive phase III trial results for immune checkpoint blockade (ICB) in MPM herald a new dawn in the fight to advance effective treatments for this cancer. Tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harber, James, Kamata, Tamihiro, Pritchard, Catrin, Fennell, Dean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438820/ https://www.ncbi.nlm.nih.gov/pubmed/34518291 http://dx.doi.org/10.1136/jitc-2021-003032

Ejemplares similares

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
por: Genova, Carlo, et al.
Publicado: (2022)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment
por: Kamata, Tamihiro, et al.
Publicado: (2022)

Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma
por: Rondon, Lizbeth, et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

Efficacy and safety of immune checkpoint blockade for brain metastases
por: Harary, Maya, et al.
Publicado: (2019)

Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade
por: Fang, Tianxu, et al.
Publicado: (2023)

The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours
por: Kamata, Tamihiro, et al.
Publicado: (2015)

Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
por: Subramanian, Madhav, et al.
Publicado: (2023)

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy
por: Xiao, Yuling, et al.
Publicado: (2022)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
por: Sun, Lu, et al.
Publicado: (2023)

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
por: Luo, Hong, et al.
Publicado: (2023)

Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade
por: Kang, Wenyi, et al.
Publicado: (2022)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
por: Napoli, Francesca, et al.
Publicado: (2021)

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma
por: Raghav, Kanwal, et al.
Publicado: (2021)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
por: Pingili, Ajeeth K., et al.
Publicado: (2021)

Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
por: Mehra, Siddharth, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023)

Fibroblast-Derived STC-1 Modulates Tumor-Associated Macrophages and Lung Adenocarcinoma Development
por: Kamata, Tamihiro, et al.
Publicado: (2020)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
por: Peng, Jianheng, et al.
Publicado: (2023)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3j0f4fitgo7nlmres89uh4443d